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Abstract 49 
SPONASTRIME dysplasia is a rare recessive skeletal dysplasia characterized by short 50 
stature, facial dysmorphism, and aberrant radiographic findings of the spine and long bone 51 
metaphysis. No causative genetic alterations for SPONASTRIME dysplasia have yet been 52 
determined. Using whole exome sequencing, we identified biallelic TONSL mutations in 10 of 13 53 
individuals with SPONASTRIME dysplasia. TONSL is a multi-domain scaffold protein that interacts 54 
with DNA replication and repair factors, and plays critical roles in resistance to replication stress and 55 
maintenance of genome integrity. We show here that cellular defects in dermal fibroblasts from 56 
individuals are complemented by expressing wild-type TONSL. In addition, in vitro cell-based assays 57 
and in silico analyses of TONSL structure support the pathogenicity of those TONSL variants. 58 
Intriguingly, a knock-in Tonsl mouse model leads to embryonic lethality, implying the physiological 59 
importance of TONSL. Overall, these findings indicate that genetic variants resulting in reduced 60 
function of TONSL cause SPONASTRIME dysplasia and highlight the importance of the TONSL in 61 
embryonic development and postnatal growth. 62 
 63 
Introduction 64 
SPONASTRIME dysplasia (MIM: 271510), the denotation of which originate from 65 
SPOndylar and NAsal alterations with STRIated MEtaphyses,1 is a very rare but distinct entity that 66 
can be categorized as a spondyloepimetaphyseal dysplasia, transmitted as an autosomal recessive trait. 67 
To date, only 15 individuals with this disorder have been reported1-10 based on the diagnostic criteria 68 
of a unique combination of clinical and radiological findings, as suggested by Langer et al.5 The 69 
major clinical features are mild to moderate short-limb type dwarfism, relatively large head with a 70 
prominent forehead, as well as epicanthic folds observed in infancy or early childhood. However, the 71 
clinical criteria are nonspecific and radiological features must be present for a diagnosis. Diagnostic 72 
criteria based on the radiological features focus on the changes in the lumbar vertebrae and 73 
metaphyseal changes in the long bones. Metaphyseal irregularities and striations, as proposed by the 74 
disease’s name, are also important diagnostic criteria, but are not seen as consistently as the lumbar 75 
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vertebral changes.5 To date, causative genetic mutations for SPONASTRIME dysplasia have not been 76 
determined, and thus a genetic test for this disease is not yet clinically available.  77 
Tonsoku-like DNA repair protein (TONSL) is a multi-domain scaffold protein that interacts 78 
with DNA replication and repair factors including anti-silencing function 1 (ASF1) , minichromosome 79 
maintenance complex component helicases (MCM helicases), H3 histone, H4 histone, and MMS22-80 
like protein (MMS22L).11-15 TONSL consists of 1,378 amino acids with annotated domains such as 81 
eight tetratricopeptide repeats (TPR), three Ankyrin (ANK) repeats, an ubiquitin-like domain (UBL), 82 
and seven leucine-rich repeats (LRR).13 It was reported that the TONSL-MMS22L heterodimer plays 83 
a key role in homologous recombination required for repairing spontaneous replication-associated 84 
DNA lesions. At the cellular level, depleting TONSL causes pronounced defects in the rate of cell 85 
proliferation and enhances the sensitivity to camptothecin (CPT), a topoisomerase 1 inhibitor that 86 
induces DNA breakage at replication forks.12,13 Specifically, TONSL-MMS22L is recruited to the 87 
sites of stalled replication forks during normal S phase by replication protein A (RPA1, RPA2 and 88 
RPA3) bound to single-strand DNA (ssDNA), and promotes RAD51 loading for strand invasion.16 89 
Therefore, it was demonstrated that small interfering RNA (siRNA)-mediated TONSL knockdown 90 
leads to loss of damage-induced RAD51 foci formation in cells treated with genotoxic agents.11,12,16  91 
In this study, in order to identify the causative genetic alteration for SPONASTRIME 92 
dysplasia, we recruited 13 individuals, including a previously reported case,10 from four different 93 
ethnicities, who satisfied the diagnostic criteria of the disease. By performing whole exome 94 
sequencing and Sanger sequencing, we identified autosomal recessive hypomorphic and loss-of-95 
function (LoF) mutations in the TONSL (MIM: 604546) gene of individuals with SPONASTRIME 96 
dysplasia. In further studies, using the dermal fibroblasts from individuals, in vitro cell-based assays, 97 
in silico struture simulation, and in vivo knock-in mouse model, we demonstrated the pathogenicity of 98 
TONSL variants, suggesting that defects in replication-associated DNA damage repair and the 99 
resultant inefficient cell proliferation due to TONSL mutations might be the underlying pathogenic 100 
mechanism for SPONASTRIME dysplasia.  101 
 102 
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Material and Methods 103 
Subjects. Written informed consent was obtained from the individuals or their parents. The 104 
Institutional Review Boards of the Seoul National University Hospital, Seoul, Republic of Korea and 105 
Samsung Medical Center, Seoul, Republic of Korea approved the studies.  106 
Whole exome sequencing (WES) and whole genome sequencing (WGS). To identify genomic 107 
variants that cause SPONASTRIME, we performed WES. Additionally, WGS was conducted in cases 108 
where only a single pathogenic TONSL allele was identified by WES (P01-1 and P01-2). Basic 109 
statistics of the WES data are summarized in Table S2. Based on the inheritance pattern of the 110 
individuals, we hypothesized that the disease follows an autosomal recessive fashion. Thus, we 111 
eliminated variants that did not satisfy the following criteria: (1) Variants showing allele frequency < 112 
1% in ESP6500 and 1000 Genome Project; (2) Variants not found in our in-house database; (3) 113 
Protein altering variants; and (4) High quality of reads (read number > 20, QS > 30, or minor allele 114 
frequency > 20%). The resulting list of variants is displayed in Table S3. For the structural variants 115 
from WGS data, Manta (0.20.2) was used with default settings and Control-FREEC (6.4) for 116 
identifying copy number variants. Window size was set as 10,000 and read counts were normalized 117 
based on GC-content bias for Control-FREEC. CNV type was classified based on genome ploidy 118 
value 2, where values below 2 denoted loss and values above 2 denoted gain. 119 
Amino acid conservation and base-level functionality analyses. To evaluate functionality of nine 120 
missense variants in TONSL, orthologous sequences from 61 mammalian species were downloaded 121 
from the UCSC browser and aligned with the human TONSL. The CADD and GERP scores across 122 
TONSL coding sequences were downloaded from dbNSFP.17  123 
Long-range PCR. Long-range PCR (LR-PCR) was conducted to analyze the exon 23 deletion of 124 
TONSL in P01-1, P01-2 and the mother using the following primers: TONSL-exon22-F: 5’-125 
GAAGAGACTGCCAAGCCAAG-3’ and TONSL-exon24-R: 5’-TACCATTTCTGTGGCCCTTC-3’. 126 
Sanger sequencing. Sequencing of TONSL candidate variants found from WES or WGS analysis 127 
were conducted using standard PCR and Sanger sequencing methods (primer sequences available 128 
upon request). Sequence data were aligned to the reference sequence Sequencher software (Gene 129 
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Codes Corporation, Ann Arbor, MI, USA). 130 
Reverse transcription-PCR and cloning.  To investigate the splicing changes caused by the splicing 131 
site and deep intronic mutations in P11, reverse transcription-PCR and cloning of the amplicon was 132 
performed. The mRNA was harvested from the circulating leukocytes of proband and parents using 133 
QIAamp RNA Blood Mini Kit (Qiagen, Germany). The cDNA were transcribed using Transcriptor 134 
First Strand cDNA Synthesis Kit and then PCR amplification was carried out using the primers 135 
TONSL4F 5’-TATGACCACTGCCAGTCGAG-3’ and TONSL11R 5’-136 
TGAGCTCCCGTAGTCTGGTT-3’, which encompass both paternal and maternal mutations. After 137 
PCR based cloning using an All in One™ PCR Cloning Kit (Biofact, Korea), 30 colonies were picked 138 
for PCR and sequencing analyses using the same primers. 139 
Cell culture, cell immortalization, mutagenesis and TONSL cell line establishment. Dermal 140 
fibroblasts from individuals were grown in high glucose and no glutamine DMEM (Gibco, 10313) 141 
supplemented with 15% fetal bovine serum (Gibco), glutamine (Gibco, 35050-061), MEM non-142 
essential amino acid (Gibco, 11140-050), penicillin and streptomycin (Gibco, 15140-122) and grown 143 
in 5% CO2 and 3% O2 at 37°C. BJ foreskin fibroblasts used as a normal control and were obtained 144 
from ATCC. HeLa, U2OS and 293T cells were grown in high glucose DMEM (Gibco, 11965) 145 
supplemented with 10% fetal bovine serum, penicillin and streptomycin (Gibco, 15140-122) and 146 
grown in 5% CO2 at 37°C. Dermal fibroblasts from individuals were transformed by human papilloma 147 
virus E6 and E7 protein and immortalized by catalytic subunit of human telomerase (hTERT) through 148 
retroviral transduction. HPV16 E6E7 genes (a gift from Howley Lab, Harvard Medical School, 149 
Boston, Massachusetts, USA) were subcloned into pMSCVneo (Clontech) and used to transform the 150 
dermal fibroblasts. pWZL-hTERT was used to immortalize the dermal fibroblasts from individuals. 151 
The gene coding wild-type TONSL was amplified from a cDNA library prepared from U2OS cells by 152 
polymerase chain reaction (PCR) with the following primers TONSL-F (5'-153 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATGAGCCTGGAGCGCGAGC-3') and 154 
TONSL-R (5'-155 
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGAGGCGCCGAAAGAAGAGC-3'). The 156 
7 
 
PCR product was cloned into a Gateway BP vector, pDONR223, using BP clonase. The pDONR223 157 
clone was sequenced and then recombined into pHAGE vectors using LR clonase (Thermo Fisher 158 
Scientific). Using the pDONR223-TONSL template, we generated the point mutation plasmids used 159 
in this study using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Genomics). The 160 
primers used to generate TONSL mutations are listed in Table S5.   161 
Fiber analysis. For replication fork stalling, P03 cells were pulse-labelled with 25 μM 5-chloro-20-162 
deoxyuridine (CldU: Sigma-Aldrich C6891), washed with PBS, pulse-labelled with 250 μM 5-iodo-163 
20-deoxyuridine (IdU; Sigma-Aldrich I7125), and harvested. Cells were washed and resuspended to 164 
5×105 cells/ml in PBS. The cells were lysed in spreading buffer (200 mM Tris-HCl, pH 7.5, 50 mM 165 
EDTA, 0.5% SDS) on glass slides. DNA fibers were spread by gravity, then fixed with 166 
methanol:acetic acid (3:1), denatured with 2.5M HCl. CldU was detected using rat anti-BrdU 167 
antibody (clone BU1/75, ICR1; Abcam, ab6326; 1:750) and IdU with mouse anti-BrdU antibody 168 
(clone B44; BD Biosciences, 347583; 1:750). Slides were fixed using 4% paraformaldehyde, then 169 
stained with Alexa Fluor 594or 488 conjugated secondary antibodies (Life Technologies). Images 170 
were acquired using a Nikon Eclipse Ni microscope with 60× oil-immersion objectives and NIS-171 
Elements software (Nikon Instruments). ImageJ software (US National Institutes of Health; NIH) was 172 
used to analyze replication fork structures (>1000 fork structures) and CldU/IdU track lengths (>300 173 
ongoing forks). For CPT treatment (DNA damage repair) fiber analysis, cells were treated with 100 174 
μM CldU for 30 minutes, then 250 μM 5-iodo-20-deoxyuridine (IdU; Sigma-Aldrich I7125) for 30 175 
minutes with 2.5 μM/50 nM CPT or DMSO. DNA plug was prepared by ~2-4.5×105 cell/plug using 176 
by low-melting agarose (Bio-Rad 161-3112), followed by lysis with 20 mg/ml Proteinase K (Roche 177 
03115828001) for two days at 50°C. To stretch the DNA fibers, 22 mm×22 mm silanized coverslips 178 
(Genomic Vision) were dipped into the DNA solution for 13 minutes and pulled out a constant speed 179 
(300 μM/s) using a Molecular Combing System (Genomic Vision MCS-001). The coverslips were 180 
baked for 4 hours at 60℃ and incubated with acid for denaturation. CldU- and IdU-labeled tracts were 181 
detected by incubating for 2 hours at room temperature (RT) with rat anti-BrdU antibody (dilution 182 
1:100 detects BrdU and CldU; Abcam 6326) and mouse anti-BrdU antibody (1:10, detects BrdU and 183 
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IdU; Becton Dickinson347580). Slides were fixed in 4% paraformaldehyde/PBS and incubated for 1 184 
hour at RT with Alexa Fluor 488-conjugated goat anti-rat antibody (dilution 1:100, A21208; 185 
Molecular Probes/Thermo Fisher) or Alexa Fluor 568-conjugated goat anti-mouse antibody (dilution 186 
1:100, A21124; Molecular Probes/Thermo Fisher). Finally, they were mounted with ProLong Gold 187 
Antifade Reagent (Molecular Probes) and stored at -20℃. DNA fibers were observed with Carl Zeiss. 188 
Axio Observer 7 & ApoTome 2 (Motorized Fluorescence Microscope with Grid Projection) 63 189 
objective. For each experiment, a total of 200 DNA fibers were analyzed, where the number of DNA 190 
fibers was measured with ImageJ. 191 
siRNA transfection, cell proliferation and CPT sensitivity assay. The siRNA targeting TONSL 192 
coding regions are listed in Table S6. Here, 3×105 cells were plated in 6-well plates and transfected 193 
siRNA in reverse transfection manner. Cells were transfected a second time after 24 hours. Then 48 194 
hours after the second transfection, 4,000 cells were plated in 4 wells (12 well plates, SPL) for cell 195 
counting, and 1,000 cells were plated in 4 wells (96 well plates, Corning #3603) for Hoechst staining. 196 
The cells in the 12-well plates were counted using Z1 Coulter Particle Counter (Beckman Coulter) 197 
and the nuclei were counted using Cytation 3 (BioTek) for Hoechst stained cells in the 96-well plates. 198 
Then, 1,000 cells were plated in 96 well plates in 4 wells and were treated with increasing 199 
concentrations of CPT 24 hours after plating. The cells were counted 5 days after treatment. Cells 200 
were then stained with Hoechst and counted using Gen 5 (BioTek). For cell lines from individuals, 201 
40,000 cells were plated in 6-well plates in triplicates, and after 24 hours, increasing concentration of 202 
CPT was treated. Four days after drug treatment, cells were passed 1:4 to 6 well plates and counted 4 203 
days after using Z1 Coulter Particle Counter (Beckman Coulter).18 204 
Immunoblot. Cell lysate was prepared by boiling cells in 95 °C for 5 minutes in 2X SDS sample 205 
buffer (RBC). For resolution of the proteins, 7.5% precast gels (Bio-Rad) were used, and 206 
immunoblotting was performed with anti-HA (Biolegend; MMS-101R, Lot B224726), anti-TONSL  207 
(Bethyl: A303-843A, Lot #1), anti-GAPDH (Santa Cruz: SC-25778, Lot K0615), anti-phosphorylated 208 
CHEK1 (Cell Signaling: 2348P, Lot #11), anti-phosphorylated CHEK2 (Cell Signaling: 2661P, Lot 209 
#11) and anti-α-Tubulin (Abfrontier: LF-PA0146, Lot MJL01-02) antibodies to detect each protein. 210 
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Immunofluorescence (BrdU/Rad51). For immunofluorescence, 3×105 cells were plated in 6-well 211 
plates (SPL) with cover glass. For HeLa and U2OS cells, siRNA was treated in reverse and forward 212 
transfection manner and plated 48 hours after the second transfection. After 24 hours, cells were either 213 
treated with CPT (500 μM) overnight or BrdU (20 μg/mL) for 4 hours, then fixed with 3.7% 214 
formaldehyde in PBS. For BrdU incorporation, the Invitrogen protocol was followed. Cells were 215 
washed in PBS and fixed in 3.7% formaldehyde in PBS for 15 minutes. After washing cells in PBS, 216 
cells were permeabilized in 0.1%Triton X-100 buffer for 20 minutes, then in 1N HCl for 10 minutes 217 
on ice. Cells were then incubated in 2N HCl for 10 minutes in room temperature (RT), then in 218 
phosphate/citric acid buffer for 10 minutes. Cells were washed in permeabilization buffer twice, then 219 
incubated with Alexa Fluor®  488 conjugated anti-BrdU primary antibody overnight at RT. For all 220 
others, cells were fixed in 3.7% formaldehyde for 15 minutes, then permeabilized with 0.1% Triton X-221 
100 for 20 minutes with PBS washing in between. After washing with PBS twice, the cells were 222 
blocked with PBG (0.2% [w/v] cold fish gelatin, 0.5% BSA in PBS) for 1 hour at room temperature. 223 
Then, the cells were incubated with 1:7000 of anti-Rad51 antibody (Abcam, Rb:ab133534, Lot #: 224 
GR219215-36), and 1:1000 anti-γ-H2A.X antibody (Cell Signaling, #9718S, Lot #13) in PBG 225 
overnight at 4°C. The following day, cells were washed three times with PBG and incubated with 226 
fluorescent-conjugated secondary antibody for 30 minutes. Secondary antibodies were purchased 227 
from Abcam (Ms Alexa Fluor®  594: ab150112; Rb Alexa Fluor®  594: ab150064; Ms Alexa Fluor®  228 
488: ab150109 and Rb Alexa Fluor®  488: ab150061). After washing with PBG three times, the 229 
coverslips were embedded in Vectashield (Vector Laboratories) supplemented with DAPI. Nikon A1 230 
confocal microscope was used equipped with a CFI-Apochromat 60X NA-1.4 oil objective, the A1-231 
DUG GaAsP multi detector unit, and the NIS-Element C-ER software. For the BrdU assay, the ratio 232 
was calculated by dividing the number of BrdU incorporated cells by the number of total cells 233 
counted. 234 
Animals and ethics statement. All mice were purchased from Taconic Biosciences (Dae Han Biolink 235 
Co., Ltd., Chungbuk, Republic of Korea) and housed at the specific pathogen-free (SPF) facility of 236 
the Yonsei Laboratory Animal Research Center. Animal experimental procedures were conducted in 237 
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accordance with the Korean Food and Drug Administration (KFDA) guidelines, reviewed, and 238 
approved by the Institutional Animal Care and Use Committees (IACUC) at Yonsei University 239 
(Permit Number: 201506-322-02).  240 
Preparation of CRISPR/Cas9 mRNA and donor DNA. Cas9 mRNA was synthesized using a 241 
mMESSAGE mMACHINE®  T7 Ultra kit (Ambion) and diluted to working concentration in 242 
endonuclease-free injection buffer (0.25 mM EDTA, 10 mM Tris, pH7.4) immediately before 243 
microinjection. A plasmid encoding the S. pyogenes Cas9 (SpCas9) protein19 was obtained from 244 
ToolGen, Inc. (Seoul, Republic of Korea). The crRNAs were designed by searching for “NGG” or 245 
“CCN (the reverse complement sequence of NGG)” sequences near the point mutation target sites. 246 
The crRNA sequences used in this study were: crRNA1 5′-GGTCCAGCCCCCTCCCATCC-3′, 247 
crRNA2 5′-GAACCCGGATGGGAGGGGGC-3′, crRNA3 5′-CCGGGTTCGAGTTCAAATTC-3′, 248 
and crRNA4 5′-CCTGAATTTGAACTCGAACC-3′. The 106-bp synthesized single stranded 249 
oligonucleotide (ssDNA) used as donor DNA was p.Arg924Trp ssDNA 5′-250 
TAGAAACTTCTGTCTTCTGACTGTCCCCTCCCTCTGTCTTTCCTGCTAGCTTCTGGTCCAGC251 
CTCCTCCTATCTGGGTTCGGGTTCAGATTCAGGATAACCTTTTCCTCATCCCCGTTCCC-3′. 252 
The tracrRNA, crRNAs targeting the Tonsl gene, and ssDNA donor for homology-directed repair were 253 
obtained from Integrated DNA Technologies (IDT). 254 
Microinjection. Microinjection of one-cell embryos was performed as previously described.20 In 255 
brief, 3–4 week old C57BL/6 female mice were superovulated by intra-peritoneal (i.p.) injections of 5 256 
IU pregnant mare serum gonadotropin (PMSG, Sigma) and 5 IU human chorionic gonadotropin 257 
(hCG, Sigma) at 48 hour intervals. The fertilized eggs were then collected from the superovulated 258 
females crossed with stud males, and were microinjected with a mixture of Cas9 mRNA (50 or 100 259 
ng/μL), four crRNAs (10, 25, or 50 ng/μL each), tracrRNA (tracrRNA mixed with crRNA at 1:1 molar 260 
ratio), and donor ssDNA (200 ng/μL). Microinjections were performed in the cytoplasm of one-cell 261 
embryos using a piezo-driven manipulator (Prime Tech), followed by embryo transfer into the 262 
oviducts of pseudo-pregnant ICR mice to produce a living mouse. 263 
Founder screening and genotyping PCR. To screen founders carrying the p.Arg924Trp mutation in 264 
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the Tonsl gene, PAGE-PCR assay was performed as previously described21 using genomic DNA 265 
obtained from newborns that were produced from the microinjected embryos. In brief, the genomic 266 
regions spanning the crRNA target site were amplified by PCR. After simply denaturing and 267 
annealing the PCR products, the resulting products were analyzed by acrylamide gel electrophoresis. 268 
Then, the candidates were cloned in T-Blunt PCR Cloning Vector (SolGent Co., Ltd., Republic of 269 
Korea), and were validated by direct sequencing analysis (Cosmobiotech Co., Ltd., Republic of 270 
Korea). The primer sequences used in PAGE-PCR were: F 5’-TGAATGCAGAGCCTGCAGAGA-3’ 271 
and R 5-TCTAGGGAGCAGAGTGCCAAG-3’. For genotyping PCR, DNA was extracted from tails 272 
or yolk sacs. Primers F, 5’-AAGCAGTCTTCAGCATGGGACT-3’ and WT R, 5’-273 
AACTCGAACCCGGATG-3’ were used to identify the Tonsl WT allele. Primers F and KI R 5’-274 
ACCCAGATAGGAGGAG-3’ were used to identify the Tonsl p.Arg924Trp allele. The primer WT R 275 
is annealed specifically to the sequence of the Tonsl WT allele, whereas KI R to the sequence of the 276 
Tonsl p.Arg924Trp allele.  277 
Embryo collection. Gestation was dated by the detection of a vaginal plug (as E0.5) or following in-278 
vitro fertilization (IVF) and embryo transfer. Embryos were either fixed in 10% neutral buffered 279 
formalin (Sigma-Aldrich) or snap-frozen in liquid nitrogen. Stereomicroscope images were generated 280 
from specimens of fixed embryos. 281 
 282 
 283 
Results 284 
Diagnosis and clinical information of individuals with SPONASTRIME dysplasia 285 
We recruited 13 individuals, including a previously reported case,10 satisfying the diagnostic 286 
criteria of the disease from four different ethnicities – Korean, Indian, Finnish and Brazilian (African 287 
black and non-Latin European). Their clinical features are presented on Table 1 and case reports (see 288 
Supplemental note). The median of height standard deviation scores (SDS) of all the individuals of 289 
this study was -4.9 (ranging from -0.9 to -10.0). They were short with height SDS down to -10, but a 290 
mildly affected individual (P03) had a height SDS of only -0.9. All the individuals recruited shared 291 
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similar facial dysmorphism (Figure 1A). Other clinical findings shared by more than one individual 292 
included short dental root, airway narrowing, cataracts and joint laxity. Radiographic features were 293 
characterized by distinct changes in vertebrae and metaphyses of the long bones. It is worth noting 294 
that the radiographic features changed and became more conspicuous with age (Figure 1B and Table 295 
S1).  296 
Identification of TONSL mutations in individuals with SPONASTRIME dysplasia 297 
To identify the pathogenic mutation causing the disease, whole exome sequencing (WES) of 298 
individuals and available family members was conducted in eight individuals from seven families 299 
(five Koreans, one Brazilian, and one Finnish; P01-1 to P07) (Tables S2 and S3). Written informed 300 
consent was obtained from each individual or their parents, and the study was approved by the 301 
Institutional Review Board. Based on the hypothesis that this disease is inherited in an autosomal 302 
recessive manner, we retrieved rare variants (<1% frequency in the public database) that were 303 
specifically harbored by the probands in homozygous or compound heterozygous status from the eight 304 
individuals. Among the individual-specific variants that followed a recessive pattern, variants in 305 
TONSL were present in four individuals (Table 2). The remaining four individuals harbored single 306 
variants in the gene and required further analysis to verify whether they also fit into the recessive 307 
model. For example, subsequent whole genome sequencing analysis of the sibling probands (P01-1 308 
and P01-2) identified an exon 23 deletion in the maternal allele, which was validated by polymerase 309 
chain reaction (PCR). Next, an additional cohort from India was recruited and subjected to singleton 310 
WES (P08 to P10), which led to the discovery of biallelic variants in TONSL. Finally, we screened 311 
two additional individuals (one Korean and one Indian) for such TONSL variants by Sanger 312 
sequencing and identified biallelic mutations in one (P11) and a single mutation in the other (P12). 313 
P11 has a splicing site variant and a deep intronic variant whose subsequent changes in mRNA were 314 
confirmed by reverse transcription-PCR. Only one mutation was identified in the TONSL gene in the 315 
three probands, P05, P06 and P12 (Table 2). Because the parents harboring the same mutation were 316 
unaffected, it is highly likely that the individuals had undetermined variants in the remaining allele of 317 
TONSL, such as a cryptic structural variation or a noncoding variation. All the TONSL mutations 318 
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identified were confirmed by Sanger sequencing (Figure S1A-B). No significant variation was found 319 
in other skeletal dysplasia-related genes in affected individuals. Ten out of thirteen individuals 320 
(76.9 %) carried one LoF allele and one missense allele (Table 2). Except for nonsense mutations, 321 
which may lead to nonsense-mediated mRNA decay, TONSL missense mutations were found in 322 
various locations throughout the protein-coding region (Figure 2A), mostly within functionally 323 
annotated domains (8 out of 9). The nine missense variants displayed complete or near-complete 324 
evolutionary conservation across vertebrate species (Figure 2B) and were found in low frequency in 325 
the healthy population (5/9 not found in the ExAC database, all nine <1.0 × 10-4). To predict the 326 
functionality of the missense variants, the CADD and GERP scores were compared with the rest of 327 
the amino acid residues of the protein and displayed significant differences (Figure 2C and Figure 328 
S2A-D). TONSL is tolerant to LoF variants (ExAC pLI = 0.00), but no individual in this study carried 329 
LoF variants in both alleles, implying a critical but minimal requirement of TONSL function for 330 
survival. 331 
 332 
Complementation of defects in dermal fibroblasts from individuals by expression of wild-type 333 
TONSL  334 
In an attempt to validate that TONSL variants are causal for the SPONASTRIME phenotype, 335 
we established primary dermal fibroblasts from two individuals, P03 and P04. Immunoblot analysis 336 
showed a pronounced decrease in TONSL levels compared to those in normal human fibroblasts, BJ 337 
cells (Figure 3A). siRNA treatment abrogated endogenous TONSL protein levels (Figure 3A and 338 
Figure S5A). To further validate the causative nature of TONSL variants, we transduced an empty 339 
vector (EV) and HA-tagged wild-type (WT) TONSL into P03 and P04 cells (Figure 3B) and 340 
performed functional complementation assays. Expressing WT TONSL successfully rescued the 341 
enhanced sensitivity to CPT (Figure 3C) and DNA damage-induced RAD51 foci formation in both 342 
cell lines (Figure 3D and E). As controls for the CPT sensitivity assay, we used BJ cells, and the 343 
FANCP(also known as SLX4) deficient dermal fibroblasts, the FANCP cells, derived from an 344 
individual with Fanconi anemia. The FANCP cells were found to be sensitive to CPT, which was 345 
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rescued by introducing wild-type SLX4 protein through lentiviral transduction.18,22 CPT sensitivity 346 
assay of P03 and P04 cells were designed similar to that of the previous FANCP cell assay by using 347 
EV and wild-type TONSL complemented cells. In addition to the normal control BJ cells, EV as well 348 
as wild-type SLX4 FANCP cells were used for comparing CPT sensitivity. In addition, to confirm the 349 
impaired DNA replication caused by TONSL variants found in individuals, BrdU incorporation assay 350 
was performed and quantified by immunofluorescence. As expected, the BrdU incorporation ratios in 351 
P03/EV and P04/EV cells were less than that in BJ cells, whereas the complemented cells showed 352 
increased BrdU incorporation (Figure 3F). In a study by Duro et al., it was reported that although 353 
TONSL knock-down cells are sensitive to CPT, they are not sensitive to hydroxyurea (HU) compared 354 
to control cells.6 In order to test if the fibroblasts from individuals with mutant TONSL display similar 355 
characteristics, we treated P03 and P04 cells with HU. Consistent with previous reports, both P03 and 356 
P04 cells were not sensitive to HU (Figure S3). As mentioned earlier, TONSL is involved in 357 
homologous recombination, and its impairment results in decreased cell proliferation and increased 358 
sensitivity to CPT.12, 13 Because homologous recombination is an important part of DNA damage 359 
repair and thus DNA replication, it is possible that TONSL variants may increase the occurrence of 360 
stalled replication fork due to DNA damage repair defects. In order to evaluate the impairment of 361 
replication restart and DNA damage repair of the mutant TONSL, we performed fiber analysis with 362 
fibroblast from P03 and normal control cell (Figure S4). We used nucleotide analogs CldU and IdU to 363 
track the first label origin and the second label origin newly synthesized DNA. Ongoing forks have 364 
both CldU and IdU tracks, whereas stalled forks can be monitored by CldU-only labeled tracks. The 365 
percentage of each tracks from the total of all CldU incorporated tracks was then calculated to 366 
compare the changes in ongoing or stalled replication forks. Compared to normal human fibroblast, 367 
the percentage of ongoing replication fork was slightly decreased in P03 cells, and the number of 368 
stalled forks was significantly increased in P03 cells compared to normal cells (Figure S4). Next, we 369 
performed fiber analysis for CPT sensitivity using P03 and P04 cells with EV and WT-TONSL and 370 
BJ cells as controls. When treated with 50 nM of CPT, P03/EV and P04/EV cells showed decreases in 371 
replication length compared to BJ cells, which were rescued by WT-TONSL (Figure 3G). Taken 372 
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together, these data display strong evidence that the TONSL variants found in individuals impair 373 
DNA replication and repair capacity, all of which were rescued by WT-TONSL, demonstrating the 374 
pathogenic nature of TONSL mutations in the disease phenotype. 375 
 376 
Validation of pathogenic TONSL mutations in in vitro cell-based assay 377 
To systematically evaluate the pathogenicity of TONSL variants found in other individuals 378 
whose primary fibroblasts were not available, we established an in vitro cell-based assay using HeLa 379 
cell lines. We focused on missense TONSL mutations since nonsense mutations may be subject to 380 
nonsense-mediated mRNA decay. First, we tested if we could recapitulate the results of previous 381 
reports showing that TONSL depletion leads to enhanced sensitivity to CPT.11,12 In order to 382 
accomplish this, we established an assay system using HeLa cell line, where mutant TONSL is 383 
expressed but the endogenous wild-type is selectively knocked down. The strategy was to establish 384 
individual HeLa cell lines that stably express each mutant TONSL by lentiviral transduction, then 385 
treating cells with siRNA targeting TONSL 3’-untranslated region (UTR), which selectively knocks 386 
down only the endogenous TONSL mRNA. If successful, the HA-tagged TONSL is expressed, and any 387 
cellular defects due to TONSL mutation can be observed without the interference of the endogenous 388 
TONSL. WT-TONSL and EV cell lines were established as positive and negative controls. To first test 389 
the siRNA’s, HeLa cells were treated with siRNA targeting the coding region and the 3’ UTR. As 390 
shown in Figure S5A-B, depleting TONSL by targeting the coding or the 3’ UTR region in HeLa cells 391 
resulted in hypersensitivity to CPT. Then, HeLa cells stably expressing the individual EV, HA-tagged 392 
WT-TONSL and the HA-tagged TONSL missense mutant were successfully established (Figure S5C). 393 
The siRNA targeting the TONSL 3 UTR selectively knocked down endogenous TONSL, but not HA-394 
tagged WT or mutant TONSL (Figure 4A). After confirming the selective knockdown of endogenous 395 
TONSL and decreased TONSL protein levels, EV, WT-TONSL and TONSL variant cells were treated 396 
with siRNA targeting TONSL 3’ UTR, and were then grown for 5 days to monitor cell proliferation. 397 
Overall, a noticeable proliferation defect was observed in TONSL variant HeLa cells compared to 398 
WT-TONSL cells (Figure 4B). Of these, proliferation of cells with P02_p.Gly973Arg, P01-1;P01-399 
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2_p.Arg934Trp, P05_p.Asp364His, and P08_p.Ser174Asn variants were significantly inhibited to a 400 
similar level as that of siTONSL-treated HeLa-EV cells (Figure 4B). This result shows that all 401 
examined TONSL variants directly impact cell proliferation, but to varying degrees. At the same time, 402 
we evaluated phosphorylated Checkpoint (CHEK1) and Checkpoint kinase 2 (CHEK2) after 403 
endogenous TONSL depletion in the individual TONSL variant HeLa cells. We found that the check-404 
point is activated in cells with proliferation defects (Figure 4C), suggesting that the functional 405 
impairment of TONSL leads to genome instability, which results in cell cycle arrest and inhibition of 406 
cell division. To further investigate the role of each TONSL variants in repairing replication-407 
associated DNA damage, a CPT sensitivity assay was performed. Consistent with the proliferation 408 
results, the CPT sensitivity of the TONSL variant cells was comparable to that of siTONSL-treated 409 
HeLa-EV cells, which lack TONSL (Figure 4D). In addition, we modeled the wild-type and TONSL 410 
variants based on the existing available structure to determine the basis of aberrant function of the 411 
TONSL variants (Figure S6). p.Glu539Lys (P03) and p.Arg558Gln (P04) altered the polar interactions 412 
between amino acids. Exon 23 deletion from individuals P01-1 and P01-2 changed the curvature of 413 
LRR domain significantly, and the p.664delLeu (P09) altered the direction of the C-terminal of the 414 
helix (Figures S6A-G). These changes deformed the overall structures, which may influence binding 415 
affinity between variant TONSL and its binding partners (Figure S6). From the studies using in vitro 416 
cell-based assay and in silico structural analyses, we conclude that the identified TONSL variants 417 
compromise TONSL functional activity, which potentially leads to human diseases. 418 
 419 
Embryonic lethality of Tonsl knock-in mouse model 420 
To better understand the pathophysiology and clinical correlations, we generated a 421 
CRISPR/Cas9-mediated Tonsl knock-in (KI) mouse carrying a p.Arg924Trp substitution in the Tonsl 422 
gene, akin to its human counterpart TONSL p.Arg934Trp variant found in individuals P01-1 and P01-423 
2 (Figure 5A-C and S7A). Heterozygous Tonsl+/Arg924Trp (HT) mice were fertile and showed normal 424 
gross morphology. Intriguingly, no offspring littermates (n = 38) carrying the biallelic p.Arg924Trp 425 
variant were obtained from heterozygous intercrosses, while their WT and HT littermates were born 426 
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in a 1:2.8 ratio (Figure 5D), suggesting that the homozygotes were not viable. For development 427 
analysis, we collected embryos from embryonic days 10.5 to 12.5 (E10.5E12.5) and observed a 428 
1:1.4:0.6 ratio of WT:HT:KI embryos (Table S4). However, all homozygous TonslArg924Trp/Arg924Trp 429 
embryos showed early embryonic lethality with fetal growth restriction at around stage E10.5 (Figure 430 
5E and S7B-D). The yolk sacs of homozygous TonslArg924Trp/Arg924Trp embryos lacked visible blood 431 
vessels and were smaller than others (Figure S7E). Consistent with in vitro cell-based assays of the 432 
human TONSL p.Arg934Trp variant, these results suggest that the Tonsl p.Arg924Trp variant is not 433 
functional, and that the lack of this functional protein is likely the major reason for embryonic 434 
lethality. Taken together, these findings demonstrated the physiological importance of functional 435 
Tonsl protein in embryonic development and the pathogenic nature of the TONSL p.Arg934Trp 436 
variant.  437 
 438 
Discussion 439 
In this study, we report the identification of TONSL mutations causative for 13 individuals 440 
with SPONASTRIME dysplasia. We demonstrate that the endogenous TONSL protein level of 441 
dermal fibroblast cells from individuals presented with SPONASTRIME dysplasia is significantly 442 
lower than that of wild-type control cells. Furthermore, we found that those cells from individuals  443 
exhibit enhanced sensitivity to CPT, reduced DNA damage-induced RAD51 foci formation, and 444 
impaired replication capacity, all of which are successfully rescued by WT-TONSL through lentiviral 445 
transduction. Given the importance of TONSL function in replication fork stability during normal S 446 
phase,23 it is reasonable to speculate that pathogenic TONSL variants result in impaired cell 447 
proliferation, which is critical for embryonic development and postnatal growth.24 Similarly, 448 
mutations in various genes important for preventing replication-associated DNA lesions have been 449 
identified in individuals with growth retardation.22,24,25  450 
We found increased phosphorylation of CHEK1 and CHEK2 (Figure 4C) in cells with 451 
TONSL variant in the absence of endogenous TONSL or siRNA-mediated TONSL depletion even 452 
without treatment of genotoxic agents. CHEK1 is mainly phosphorylated by Ataxia-telangiectasia and 453 
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Rad3 related (ATR), and deleterious mutations in the ATR (MIM:601216) gene which results in 454 
Seckel syndrome (MIM: 210600), characterized by microcephaly, dwarfism, progeria, and mental 455 
retardation.25,26 ATR responds to a variety of DNA damage, and together with ATR interacting 456 
protein (ATRIP), recognizes RPA bound to single stranded DNA, which is often the result of a stalled 457 
replication fork.27 We observed that mutation in TONSL did not affect RPA foci formation in response 458 
to CPT-induced DNA damage in cells from SPONASTRIME dysplasia individuals (unpublished 459 
data), implying that TONSL functions downstream of ATR activation. Therefore, it is possible to 460 
speculate that alterations in the ATR, which function upstream of TONSL, may lead to broader 461 
defects, whereas loss of TONSL function may cause milder disease phenotypes such as 462 
SPONASTRIME dysplasia. It remains unknown why alterations in TONSL result specifically in 463 
SPONASTRIME dysplasia, and understanding the genotype to phenotype correlation requires further 464 
study.  465 
Our knock-in mouse model clearly demonstrated that even a single point mutation, 466 
p.Arg924Trp, corresponding to p.Arg934Trp identified in human SPONASTRIME dysplasia, causes 467 
embryonic lethality in mouse. Although this finding in the mouse model does not directly translate to 468 
the pathogenicity of human disease, it provides evidence supporting that the TONSL p.Arg934Trp 469 
variant might be causative of SPONASTRIME dysplasia, and highlights the physiological importance 470 
of TONSL. Homozygous p.Arg924Trp variant in mice Tonsl has severe developmental impact, where 471 
fetal growth retardation was observed approximately at E10.5, resulting in embryonic lethality. 472 
However, the heterozygotes surviving to adulthood show no apparent defects. Consistent with the in 473 
vitro cell-based assay (Figure 4B-D), these results suggest that Tonsl proteins carrying the 474 
p.Arg924Trp variant are not functional, and that the lack of this functional protein is considered to be 475 
the main reason for embryonic lethality of Tonsl KO mouse (Brendan Lee, personal communications) 476 
and even our KI models. However, unlike in mouse, the human TONSL p.Arg934Trp variant is found 477 
in a subgroup of individuals with SPONASTRIME dysplasia. The discrepancy between human and 478 
mouse phenotypes might be due to the difference in transcript isoforms found in humans and mice. 479 
According to the GENCODE basic project,28 two transcripts are predicted to be translated in humans, 480 
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whereas mouse only have one transcript. Among the two transcripts in humans, the shorter isoform 481 
lacks the domain containing the Arg934 residue as well as the UBL and LRR domains. Whether the 482 
shorter isoform has any function in humans has yet to be elucidated, but the possibility that it provides 483 
partial function for survival cannot be excluded. More research is needed to understand the TONSL 484 
variants, since the presence of another TONSL isoform could have prevented lethality in humans. 485 
Although further study is required to understand how the decreased function of TONSL leads to the 486 
specific phenotype of SPONASTRIME dysplasia, we believe that our findings increase our 487 
understanding of the pathogenesis of this disease.  488 
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Figure Titles and Legends  609 
 610 
Figure 1. Characteristic facial appearance and radiographic findings of individuals with 611 
SPONASTSRIME dysplasia.  (A) Facial photos of individuals from three different ethnicities. They 612 
share midfacial hypoplasia, depressed nasal root, short and upturned nose, prognathism, and a relatively 613 
large head size with a prominent forehead. P05 at age 5 years, P06 at age 5 years, and P08 at age 13 614 
years. (B) Lateral spine view of P02 at age 3 years and 8 months (3.8) showing taller anterior vertebral 615 
body and convex anterior endplates, and that of P01-2 at age 13 years showing biconcavity of the 616 
endplates. Hip and knee anteroposterior views of P02 at age 3.8 years showing metaphyseal irregularity 617 
and vertical striation and small, dysplastic epiphyses, and those of P01-2 showing residual avascular 618 
necrosis of the left femoral head, and mixed dense striations and lucent area at the metaphysis of the 619 
knee. 620 
 621 
Figure 2. TONSL mutations identified in individuals with SPONASTRIME dysplasia.  (A) 622 
Pathogenic variants in TONSL found from SPONASTRIME individuals are displayed on TONSL 623 
protein with known functional domains. Variants in red were analyzed for variant functionality. (B) 624 
Evolutionary conservation of the nine missense variants found in SPONASTRIME individuals. (C) 625 
As parameters of missense variant ("Pathogenic") functionality of individuals, CADD and GERP 626 
values were plotted along with residues that overlapped with the ExAC database ("ExAC") and 627 
residues that were not polymophic ("Other residues"). 628 
 629 
Figure 3. Complementation of dermal fibroblasts from individuals P03 and P04 with the TONSL 630 
cDNA.  (A) TONSL protein levels and corresponding siRNA-mediated TONSL depletion of cells 631 
from individuals with SPONASTRIME dysplasia. BJ cells were used as a normal control. The basal 632 
TONSL protein level in cells derived from individuals was lower than that in BJ cells, and all were 633 
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successfully depleted by siRNA treatment. C: siControl, T: siTONSL. (B) Stable protein level of wild-634 
type TONSL through lentiviral transduction in fibroblasts derived from both P03 and P04. EV and 635 
WT denote the empty vector and wild-type, respectively. The asterisk indicates the cross-reacting 636 
band. (C) Cells from individuals were sensitive to CPT, which were rescued to a level comparable to 637 
that of BJ cells by transducing WT-TONSL. The indicated cells in triplicate were exposed to different 638 
concentration of CPT ranging 0-32 nM. After 5 days, the number of the cells were counted using a 639 
coulter counter, and the total number of cells at each concentration was divided by the number of 640 
untreated cells. FANCP/EV, a Fanconi anemia-derived cell line lacking Slx4, and the genetically 641 
isogenic SLX4 complemented cells, FANCP/WT-SLX4 were used as controls. The error bars 642 
represent the standard deviation (SD) of three replicates. (D) Representative images of CPT-induced 643 
DNA damage Rad51 and γH2A.X foci. P03/EV, P03/WT-TONSL, P04/EV and P04/WT-TONSL cells 644 
were treated with CPT (50 nM) overnight, followed by fixing and staining with anti-RAD51 and anti-645 
γH2A.X antibodies. Impaired DNA damage induced RAD51 foci formation of those cells from 646 
individuals was recovered to that of normal cells by transducing WT-TONSL. (E) Statistical analysis 647 
of Rad51 foci. Percentage was calculated by counting nuclei with n≥10 Rad51 foci divided by the 648 
total nuclei for non-treated cells, or divided by γH2A.X positive nuclei for CPT treated cells. The 649 
error bars represent the SD. (F) BrdU incorporation into DNA was reduced in P03/EV and P04/EV 650 
cells, which were rescued to a normal level by transducing WT-TONSL. The BrdU incorporation ratio 651 
was calculated by dividing the number of BrdU incorporated cells by the number of total cells 652 
counted. The error bars represent the SD of three replicates. (G) DNA fiber analysis of CPT-treated 653 
SPONASTRIME individual-derived cell lines. BJ cells were used as control. Schematic of the 654 
experiment is shown on the top and the representative DNA fiber is shown on bottom. The red line 655 
indicates median value; **: p = 0.003; ***: p <0.001. 656 
 657 
Figure 4. In vitro cell-based assay of TONSL variants shows defects in cell proliferation and 658 
enhanced sensitivity to camptothecin.  (A) Protein level of recombinant wild-type or individual 659 
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TONSL variant in HeLa cells upon endogenous TONSL depletion using siRNA against the TONSL 3’ 660 
UTR. The TONSL antibody is able to detect both endogenous and HA-tagged TONSL, whereas the 661 
HA antibody is not able to detect endogenous TONSL. The asterisk indicates the cross-reacting band. 662 
(B) Cell proliferation assay showing varied proliferation rate of cells expressing mutant TONSL. EV 663 
cells were treated with either non-targeting siCtrl or siTONSL targeting the 3 UTR. The rest of the 664 
cells were treated with siTONSL targeting the 3 UTR. The cell proliferation rate was normalized to 665 
the cell number on day 1. Error bar represents SD of three replicates. siCtrl: siControl. (C) TONSL 666 
variants in the absence of endogenous TONSL lead to checkpoint activation. Whole cell extracts of 667 
HeLa cells expressing mutant TONSL were treated with siRNA against 3’ UTR and analyzed by 668 
immunoblot with DNA damage response factors, phosphorylated CHEK1 (pCHEK1) or 669 
phosphorylated CHEK2 (pCHEK2). (D) TONSL variant cell lines were treated with 3 UTR siRNA as 670 
in b, then treated with increasing concentrations of CPT. Cells were stained with Hoechst and nuclei 671 
were counted 5 days after CPT treatment. Cell survival was normalized to that in vehicle-treated cells. 672 
The error bars represent SD from three replicates. 673 
 674 
Figure 5. Generation and analysis of homozygous Tonsl p.Arg924Trp knock-in mouse using 675 
CRISPR-Cas9. (A) A schematic diagram showing the mouse Tonsl locus and the enlarged sequences 676 
of the exon 18 of the Tonsl gene, along with the sequences of the TonslArg924Trp allele. Blue letters in 677 
the TonslWT allele indicate a proto-spacer adjacent motif (PAM) sequence. Red letters indicate the 678 
substitution (C to T) target nucleotide in the TonslWT and the TonslArg924Trp alleles. The amino acid 679 
sequences from the TonslWT and the TonslArg924Trp alleles are shown at the top of the nucleotide 680 
sequences. The substituted nucleotides for synonymous and target mutations are shown at the bottom 681 
of the TonslArg924Trp allele sequences by black and red asterisks (*), respectively. Forward (F) and 682 
Reverse (R) PCR primers for genotyping are indicated. (B) Genotyping PCR for the TonslWT and the 683 
TonslArg924Trp alleles. The upper and bottom panels show the PCR products that were amplified from 684 
the TonslWT (115 bp) and the TonslArg924Trp (108 bp) alleles, respectively. (C) Chromatogram 685 
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displaying the sequence of the TonslWT and the TonslArg924Trp locus. (D) Genotype distribution of 686 
offspring from heterozygous intercrosses. (E) Gross morphology of whole embryos at stage E11.5. 687 
Tonsl+/+ and Tonsl+/Arg924Trp mouse embryos show normal development, whereas TonslArg924Trp/Arg924Trp 688 
embryo exhibits a growth retardation with the abnormal development of eyes and limbs.   689 
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Table 1. Clinical features of individuals in this series 
ID P01-1 a P01-2 a P02 P03 P04 P05 P06 P07 b P08 P09 P10 P11 P12 
Ethnicity Korean Korean Korean Korean 
Brazilian 
(African 
black and 
non-Latin 
European) 
Korean Finnish Korean Indian Indian Indian Korean Indian 
Age of initial 
presentation 
(years. months) 
8.5 6 0.2 13 2.2 2.7 At birth 36 13 14 11 3.5 1.9 
Gender F M M M M F F M M F F F F   
Consanguinity No No No No Yes No No No No  No No No No 
Initial 
presentation 
short 
stature 
short 
stature 
short stature 
radiographic 
abnormality 
of knee 
short 
stature 
short 
stature 
short 
stature 
neck and 
shoulder pain 
short 
stature 
short 
stature 
short 
stature and 
limb 
deformity 
short stature 
short 
stature 
Height (cm) 
(SDS) 
104.1  
(-3.6) 
93.4   
(-4.7) 
47.9 (-4.9) 145.2 (-0.9) 76 (-4.0) 74 (-4.5) 40 (-5.6) 136 (-6.2) 
120  
(-4) 
119  
(-7) 
93 (-10) 73.6 (-5.6) 
53   
(-10) 
Age of latest 
measurement 
(years) 
17.5 15 5.7  13 6 12.6 37 13 14 11 4.2 2 
Ht cm (SDS) 
(latest) 
124.4  
(-6.8) 
143.5  
(-4.8) 
82.6 (-6.0)  122 (-4.6) 98.8 (-3.4) 
85.8    
(-10.4) 
136        
(-6.2 ) 
120  
(-4) 
119  
(-7) 
93 (-10) 80.6 (-5.8)  
Facial 
dysmorphism 
(+) (+) (+) (+) (+) (+) (+) (+) (+) (+) (+) (+) (+) 
Cognitive 
impairment 
(-) (-) (-) (-) borderline (-) (-) (-) (-) (-) (-) (-) (-) 
Other findings 
short 
dental 
roots 
short 
dental 
roots 
hypothyroidism; 
nystagmus; 
hypospadias; 
airway 
narrowing c 
 
recurrent 
pneumonia 
in the 1st 
year; short 
dental roots 
hypothyroi
dism; 
recurrent 
pneumonia 
until age 5 
years; 
precocious 
puberty 
cataracts; 
cerebro-
vascular 
aneurysm 
rupture; 
weak 
voice 
Arnold-Chiari 
malformation; 
cataracts 
  joint laxity 
joint laxity; 
hip 
subluxation; 
airway 
narrowing c 
 
a These two individuals are siblings 
b Previously reported (Jeong et al.10) 
c Airway narrowing was composed of glottic narrowing and diffuse tracheal narrowing. 
M: male, F: female, SDS: standard deviation score 
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Table 2. TONSL mutations identified in 13 individuals and their predicted protein changes 
 
a These two individuals are siblings 
b g.145657122_145658684del 
c Paternal allele harbors a substitution followed by deletion of one nucleotide. 
d Paternal allele harbors a substitution and an in-frame deletion. 
e RT-PCR revealed mRNA sequence change, predicting a truncated protein or nonsense-mediated mRNA decay  
f RT-PCR and cloning its products revealed wild-type (14/25) and two different mutant mRNAs formed by retention of a part of intron 10 (5/25) and by skipping 
of a part of exon 11 (6/25), which predicted these two different polypeptides. 
g All the individuals with two or three mutations were confirmed to be biallelic by testing the parents, except P07, whose parents had already passed away, by 
testing the siblings. 
WES: whole exome sequencing 
ID Mutation 1 Mutation2 Genetic study 
P01-1 a exon 23 deletion b  c.2800C>T p.Arg934Trp quad WES 
P01-2 a exon 23 deletion b  c.2800C>T p.Arg934Trp quad WES 
P02 c.1531C>T p.Gln511* c.2917G>A p.Gly973Arg trio WES 
P03 c.735C>G/ c.737delT c p.Cys245Trpfs*20 c.1615G>A p.Glu539Lys trio WES 
P04 c.1673G>A p.Arg558Gln c.1673G>A p.Arg558Gln trio WES 
P05 c.1090G>C p.Asp364His Not identified Not identified quad WES 
P06 c.578+1G>T  Not identified Not identified trio WES 
P07 g c.2907C>A p.Tyr969* c.3862G>C p.Glu1288Gln singleton WES 
P08 c.1471_1472delTC p.Ser491Argfs*65 c.521G>A p.Ser174Asn singleton WES 
P09 c.1459G>A / c.1989_1991del d 
p.Glu487Lys / 
p.664delLeu 
c.125G>A p.Arg42His singleton WES 
P10 c.295delT p.Ser99fs*59 c.1459G>A p.Glu487Lys singleton WES 
P11 c.578+1G>A p.Thr151Argfs*42 e c.1291-11_1291-14delCCTC p.Arg431Profs*6/ p.431_441del f Sanger 
P12 c.1459G>A p.Glu487Lys Not identified Not identified Sanger 
